Leukemia Clinical Trials in Los Angeles

Showing 641-660 of 1,049 trials

A Study of LY3023414 in Participants With Advanced Cancer

NCT01655225

The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.

Advanced CancerMetastatic CancerNon-Hodgkin's Lymphoma+3 more

Eli Lilly and Company156 participantsStarted Jul 2012

Los Angeles, California, United States • New York, New York, United States • Oklahoma City, Oklahoma, United States +5 more locations

Active Not RecruitingPhase 2< 1 mile

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

NCT03836352

This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.

Ovarian CancerHepatocellular CarcinomaNon-small Cell Lung Cancer+2 more

ImmunoVaccine Technologies, Inc. (IMV Inc.)184 participantsStarted Dec 2018

Tucson, Arizona, United States • Los Angeles, California, United States • Boca Raton, Florida, United States +20 more locations

A Study of LY3023414 in Participants With Advanced Cancer

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Leukemia Trials in Other Cities

CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Safety Study of MGA271 in Refractory Cancer

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Double Cord Versus Haploidentical (BMT CTN 1101)

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

Other Conditions in Los Angeles